Von dem Buch NEW Drugs for HER-2-Positive Breast Cancer by Elisabeth Bergen Paperback Book (E haben wir 3 gleiche oder sehr ähnliche Ausgaben identifiziert!
Falls Sie nur an einem bestimmten Exempar interessiert sind, können Sie aus der folgenden Liste jenes wählen, an dem Sie interessiert sind:
100%: Sous la direction de: Maria Sibilia, Sous la direction de: Christoph C. Zielinski, Sous la direction de: Rupert Bartsch, Sous la direction de: Thomas Grunt: NEW Drugs for HER-2-Positive Breast Cancer by Elisabeth Bergen Paperback Book (E (ISBN: 9783034803182) 2013, Springer Nature, in Englisch, Taschenbuch.Nur diese Ausgabe anzeigen…
62%: Sous la direction de: Christoph C. Zielinski, Sous la direction de: Maria Sibilia, Sous la direction de: Thomas Grunt, Sous la direction de: Rupert Bartsch: Drugs for HER-2-positive Breast Cancer (Milestones in Drug Therapy) (ISBN: 9783034600934) 2011, in Englisch, Broschiert.Nur diese Ausgabe anzeigen…
38%: Herausgeber: Maria Sibilia, Herausgeber: Christoph C. Zielinski, Herausgeber: Rupert Bartsch, Herausgeber: Thomas W. Grunt: Drugs for HER-2-positive Breast Cancer (Milestones in Drug Therapy) (ISBN: 9783034600941) 2011, 2011. Ausgabe, in Englisch, auch als eBook.Nur diese Ausgabe anzeigen…
NEW Drugs for HER-2-Positive Breast Cancer by Elisabeth Bergen Paperback Book (E
13 Angebote vergleichen
| Preise | 2013 | 2014 | 2015 | 2016 | 2023 |
|---|---|---|---|---|---|
| Schnitt | € 119,62 | € 151,86 | € 198,06 | € 176,66 | € 160,49 |
| Nachfrage |
1
Symbolbild
Drugs for HER-2-Positive Breast Cancer
DE HC NWISBN: 9783034600934 bzw. 3034600933, in Deutsch, Springer, gebundenes Buch, neu.
Von Händler/Antiquariat, BuySomeBooks [52360437], Las Vegas, NV, U.S.A.
Hardcover. 119 pages. Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1-2 inhibitors such as lapatinib (TykerbTyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting. This item ships from multiple locations. Your book may arrive from Roseburg,OR, La Vergne,TN, Momence,IL, Commerce,GA.
Hardcover. 119 pages. Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1-2 inhibitors such as lapatinib (TykerbTyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting. This item ships from multiple locations. Your book may arrive from Roseburg,OR, La Vergne,TN, Momence,IL, Commerce,GA.
2
Symbolbild
Drugs for HER-2-positive Breast Cancer (2011)
DE HC NWISBN: 9783034600934 bzw. 3034600933, in Deutsch, Springer, gebundenes Buch, neu.
Von Händler/Antiquariat, Herb Tandree Philosophy Books [17426], Stroud, United Kingdom.
9783034600934 Hardback, This listing is a new book, a title currently in-print which we order directly and immediately from the publisher.
9783034600934 Hardback, This listing is a new book, a title currently in-print which we order directly and immediately from the publisher.
3
Drugs for HER-2-Positive Breast Cancer (2013)
DE PB NWISBN: 9783034803182 bzw. 3034803184, in Deutsch, Springer Basel, Taschenbuch, neu.
Lieferung aus: Niederlande, Vermoedelijk 4-6 weken.
bol.com.
Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastu... Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.Taal: Engels;Afmetingen: 7x235x155 mm;Gewicht: 195,00 gram;Verschijningsdatum: februari 2013;ISBN10: 3034803184;ISBN13: 9783034803182; Engelstalig | Paperback | 2013.
bol.com.
Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastu... Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.Taal: Engels;Afmetingen: 7x235x155 mm;Gewicht: 195,00 gram;Verschijningsdatum: februari 2013;ISBN10: 3034803184;ISBN13: 9783034803182; Engelstalig | Paperback | 2013.
5
Symbolbild
Drugs for HER2-positive Breast Cancer (2011)
DE NWISBN: 9783034600934 bzw. 3034600933, in Deutsch, Springer Basel Ag Jan 2011, neu.
Von Händler/Antiquariat, Rhein-Team Lörrach Ivano Narducci e.K. [57451429], Lörrach, BW, Germany.
- Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting. 110 pp. Englisch.
- Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting. 110 pp. Englisch.
6
Drugs for HER-2-positive Breast Cancer
~EN PB NWISBN: 9783034803182 bzw. 3034803184, vermutlich in Englisch, Springer Nature, Taschenbuch, neu.
Lieferung aus: Deutschland, Lagernd, zzgl. Versandkosten.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
7
Drugs for HER-2-positive Breast Cancer
~EN HC NWISBN: 9783034600934 bzw. 3034600933, vermutlich in Englisch, Springer Nature, gebundenes Buch, neu.
Lieferung aus: Deutschland, Lagernd, zzgl. Versandkosten.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
8
Drugs for HER-2-positive Breast Cancer
DE NW EBISBN: 9783034600934 bzw. 3034600933, in Deutsch, Springer Basel, neu, E-Book.
Lieferung aus: Vereinigte Staaten von Amerika, E-Book zum download.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
9
Symbolbild
Maria Sibilia (Editor), Christoph C. Zielinski (Editor), Rupert Bartsch (Editor), Thomas W. Grunt (Editor)
Drugs for HER-2-positive Breast Cancer (Milestones in Drug Therapy) (2011)
DE HC NWISBN: 9783034600934 bzw. 3034600933, in Deutsch, Springer, gebundenes Buch, neu.
Von Händler/Antiquariat, ExtremelyReliable [8304062], RICHMOND, TX, U.S.A.
This item is printed on demand.
This item is printed on demand.
10
Drugs for HER-2-Positive Breast Cancer (2013, Paperback)
EN PB NWISBN: 9783034803182 bzw. 3034803184, in Englisch, Taschenbuch, neu.
Lieferung aus: Vereinigte Staaten von Amerika, Lieferart: Free, Lieferung: Vereinigte Staaten von Amerika, Artikelstandort: USA, Versandkostenfrei.
Von Händler/Antiquariat, barnesandnobleinc - Barnes and Noble Store.
Sold directly by Barnes & Noble, Festpreisangebot.
Von Händler/Antiquariat, barnesandnobleinc - Barnes and Noble Store.
Sold directly by Barnes & Noble, Festpreisangebot.
Lade…